Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice

International Journal of Cardiology

Volumn 216, Issue , 2016, Pages 85-91

  Pradhan, Kabita ^a   Sydykov, Akylbek ^a   Tian, Xia ^a   Mamazhakypov, Argen ^a   Neupane, Balram ^a   Luitel, Himal ^a   Weissmann, Norbert ^a   Seeger, Werner ^a,b   Grimminger, Friedrich ^a   Kretschmer, Axel ^c   Stasch, Johannes Peter ^c   Ghofrani, Hossein Ardeschir ^a   Schermuly, Ralph Theo ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Heart failure; Pulmonary hypertension; Riociguat; Sildenafil; Transverse aortic constriction

Indexed keywords

COLLAGEN; PLACEBO; RIOCIGUAT; SILDENAFIL; CYCLIC GMP; GUANYLATE CYCLASE; NITRIC OXIDE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BLOOD PRESSURE; C57BL/6N MOUSE; COLLAGEN METABOLISM; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE FUNCTION; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; MOUSE; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RIGHT VENTRICULAR SYSTOLIC PRESSURE; TRANSVERSE AORTIC CONSTRICTION; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HEART FUNCTION TEST; HUMAN; HYPERTENSION, PULMONARY; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CYCLIC GMP; DISEASE MODELS, ANIMAL; HEART FUNCTION TESTS; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; SILDENAFIL CITRATE; SOLUBLE GUANYLYL CYCLASE; TREATMENT OUTCOME;

EID: 84964607681     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.04.098     Document Type: Article

References (39)

1. G. Simonneau, M.A. Gatzoulis, I. Adatia, D. Celermajer, C. Denton, A. Ghofrani, and et al. Updated clinical classification of pulmonary hypertension J. Am. Coll. Cardiol. 62 2013 D34 D41
2. T.J. Corte, T.A. McDonagh, and S.J. Wort Pulmonary hypertension in left heart disease: a review Int. J. Cardiol. 156 2012 253 258
3. J. Kjaergaard, D. Akkan, K.K. Iversen, E. Kjoller, L. Kober, C. Torp-Pedersen, and et al. Prognostic importance of pulmonary hypertension in patients with heart failure Am. J. Cardiol. 99 2007 1146 1150
4. S. Ghio, A. Gavazzi, C. Campana, C. Inserra, C. Klersy, R. Sebastiani, and et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure J. Am. Coll. Cardiol. 37 2001 183 188
5. F. Grigioni, L. Potena, N. Galie, F. Fallani, M. Bigliardi, F. Coccolo, and et al. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure J. Heart Lung Transplant. 25 2006 1241 1246
6. M.M. Hoeper, J.A. Barbera, R.N. Channick, P.M. Hassoun, I.M. Lang, A. Manes, and et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension J. Am. Coll. Cardiol. 54 2009 S85 S96
7. D.A. Kass, E. Takimoto, T. Nagayama, and H.C. Champion Phosphodiesterase regulation of nitric oxide signaling Cardiovasc. Res. 75 2007 303 314
8. E. Takimoto, H.C. Champion, M. Li, S. Ren, E.R. Rodriguez, B. Tavazzi, and et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load J. Clin. Invest. 115 2005 1221 1231
9. E.J. Tsai, Y. Liu, N. Koitabashi, D. Bedja, T. Danner, J.F. Jasmin, and et al. Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation Circ. Res. 110 2012 295 303
10. P. Pokreisz, S. Vandenwijngaert, V. Bito, A. Van den Bergh, I. Lenaerts, C. Busch, and et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice Circulation 119 2009 408 416
11. E. Takimoto, H.C. Champion, M. Li, D. Belardi, S. Ren, E.R. Rodriguez, and et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy Nat. Med. 11 2005 214 222
12. M. Gheorghiade, C.N. Marti, H.N. Sabbah, L. Roessig, S.J. Greene, M. Bohm, and et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure Heart Fail. Rev. 18 2013 123 134
13. J.P. Stasch, P. Pacher, and O.V. Evgenov Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease Circulation 123 2011 2263 2273
14. V. Mitrovic, A.F. Hernandez, M. Meyer, and M. Gheorghiade Role of guanylate cyclase modulators in decompensated heart failure Heart Fail. Rev. 14 2009 309 319
15. C.J. Rhodes, A. Davidson, J.S. Gibbs, J. Wharton, and M.R. Wilkins Therapeutic targets in pulmonary arterial hypertension Pharmacol. Ther. 121 2009 69 88
16. A.C. de Almeida, R.J. van Oort, and X.H. Wehrens Transverse aortic constriction in mice J. Vis. Exp. 2010
17. H.B. Thibault, B. Kurtz, M.J. Raher, R.S. Shaik, A. Waxman, G. Derumeaux, and et al. Noninvasive assessment of murine pulmonary arterial pressure: validation and application to models of pulmonary hypertension Circ. Cardiovasc. Imaging. 3 2010 157 163
18. F. Tournoux, B. Petersen, H. Thibault, L. Zou, M.J. Raher, B. Kurtz, and et al. Validation of noninvasive measurements of cardiac output in mice using echocardiography J. Am. Soc. Echocardiogr. 24 2011 465 470
19. F.C. Weisel, C. Kloepping, A. Pichl, A. Sydykov, B. Kojonazarov, J. Wilhelm, and et al. Impact of S-adenosylmethionine decarboxylase 1 on pulmonary vascular remodeling Circulation 129 2014 1510 1523
20. R.T. Schermuly, E. Dony, H.A. Ghofrani, S. Pullamsetti, R. Savai, M. Roth, and et al. Reversal of experimental pulmonary hypertension by PDGF inhibition J. Clin. Investig. 115 2005 2811 2821
21. R.M. Blanton, E. Takimoto, A.M. Lane, M. Aronovitz, R. Piotrowski, R.H. Karas, and et al. Protein kinase g ialpha inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo J. Am. Heart Assoc. 1 2012 e003731
22. G. Boerrigter, L.C. Costello-Boerrigter, A. Cataliotti, T. Tsuruda, G.J. Harty, H. Lapp, and et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure Circulation 107 2003 686 689
23. D. Fraccarollo, P. Galuppo, S. Motschenbacher, H. Ruetten, A. Schafer, and J. Bauersachs Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition Basic Res. Cardiol. 109 2014 421
24. J. Yin, M. Kukucka, J. Hoffmann, A. Sterner-Kock, J. Burhenne, W.E. Haefeli, and et al. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure Circulation. Heart Fail. 4 2011 198 206
25. T. Nagayama, S. Hsu, M. Zhang, N. Koitabashi, D. Bedja, K.L. Gabrielson, and et al. Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition J. Mol. Cell. Cardiol. 46 2009 560 567
26. T. Nagayama, S. Hsu, M. Zhang, N. Koitabashi, D. Bedja, K.L. Gabrielson, and et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload J. Am. Coll. Cardiol. 53 2009 207 215
27. S. Geschka, A. Kretschmer, Y. Sharkovska, O.V. Evgenov, B. Lawrenz, A. Hucke, and et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats PLoS ONE 6 2011 e21853
28. E. Patrucco, K. Domes, M. Sbroggio, A. Blaich, J. Schlossmann, M. Desch, and et al. Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis Proc. Natl. Acad. Sci. U. S. A. 111 2014 12925 12929
29. H. Masuyama, T. Tsuruda, Y. Sekita, K. Hatakeyama, T. Imamura, J. Kato, and et al. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart Hypertens. Res. 32 2009 597 603
30. H. Masuyama, T. Tsuruda, J. Kato, T. Imamura, Y. Asada, J.P. Stasch, and et al. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats Hypertension 48 2006 972 978
31. W. Gong, M. Yan, J. Chen, S. Chaugai, C. Chen, and D. Wang Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor beta-induced Smad signaling Front. Med. 8 2014 445 455
32. O.H. Cingolani, X.P. Yang, Y.H. Liu, M. Villanueva, N.E. Rhaleb, and O.A. Carretero Reduction of cardiac fibrosis decreases systolic performance without affecting diastolic function in hypertensive rats Hypertension 43 2004 1067 1073
33. A. Palazzuoli, M. Beltrami, M. Pellegrini, and R. Nuti Natriuretic peptides and NGAL in heart failure: does a link exist? Clinica chimica acta; international journal of clinical chemistry 413 2012 1832 1838
34. M. Rosenberg, C. Zugck, M. Nelles, C. Juenger, D. Frank, A. Remppis, and et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure Circ. Heart Fail. 1 2008 43 49
35. L. Moore, D. Fan, R. Basu, V. Kandalam, and Z. Kassiri Tissue inhibitor of metalloproteinases (TIMPs) in heart failure Heart Fail. Rev. 17 2012 693 706
36. Y. Chen, H. Guo, D. Xu, X. Xu, H. Wang, X. Hu, and et al. Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease Hypertension 59 2012 1170 1178
37. R. Dumitrascu, N. Weissmann, H.A. Ghofrani, E. Dony, K. Beuerlein, H. Schmidt, and et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling Circulation 113 2006 286 295
38. M. Lang, B. Kojonazarov, X. Tian, A. Kalymbetov, N. Weissmann, F. Grimminger, and et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats PLoS ONE 7 2012 e43433
39. M.A. Borgdorff, B. Bartelds, M.G. Dickinson, M.P. van Wiechen, P. Steendijk, M. de Vroomen, and et al. Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload Am. J. Phys. Heart Circ. Phys. 307 2014 H361 H369